The American Heart Association (AHA) officially released the "2025 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association" on January 27, 2025. This report systematically compiles the latest statistics on major cardiovascular diseases worldwide, while simultaneously integrating relevant outcome indicators, including quality of care, procedures, and economic costs, and updating the global prevalence patterns and evolving trends of diverse risk factors impacting cardiovascular health, providing essential guidance for the prevention, diagnosis, and treatment of cardiovascular diseases. Synthesizing insights from this pivotal report and other relevant studies, this article highlights key findings concerning the global prevalence and mortality of heart diseases, associated risk factors, and emerging diagnostic and therapeutic technologies.
Objective To analyze the prevalence of leukemia in China from 1990 to 2019, predict the incidence, morbidity and mortality of leukemia in China from 2020 to 2040, and provides reference for the formulation of leukemia-related prevention and treatment strategies in China. Methods Based on the 2019 Global Burden of Disease database, the incidence, morbidity and mortality data of leukemia in China from 1990 to 2019 were collected, and the rate of change and annual estimated percentage of change (EAPC) were used to describe the epidemic trend of the disease. The Autoregressive Moving Average (ARIMA) model was used to predict the prevalence of leukemia in China from 2020 to 2040. Results In 2019, the age-standardized incidence, age-standardized prevalence and age-standardized mortality rate of leukemia in China decreased by 17.62%, 10.97%, and 41.56%, respectively, compared with 1990, and an average annual decrease of 1.06%, 0.89%, and 2.05%, respectively (P<0.05). From 1990 to 2019, the reduction age-standardized incidence rate, age-standardized prevalence rate and age-standardized mortality rate in Chinese women (EAPC was 1.56%, 1.38%, and 2.62%, respectively) was higher than that of men (EAPC was 0.61%, 0.43%, and 1.59%, respectively). In 2019, the incidence and prevalence were highest in the age group under 5 years of age, and the mortality rate was the highest in the age group over 80 years old. The prediction results of ARIMA model showed that the age-standardized incidence rate and prevalence of leukemia in China showed an increasing trend from 2020 to 2040, while the age-standardized mortality rate showed a decreasing trend. It is estimated that by 2040, the age-standardized incidence rate, age-standardized prevalence rate, and age-standardized mortality rate of leukemia will be 14.06/100 000, 108.23/100 000, and 2.83/100 000. Conclusions From 1990 to 2019, the age-standardized incidence rate, age-standardized prevalence rate and age-standardized mortality rate of leukemia in China decreased year by year, but they were still at a high level. The prediction results show that the age-standardized incidence rate and age-standardized prevalence rate of leukemia in China will continue to increase from 2020 to 2040, and it is necessary to continue to strengthen the surveillance, prevention and control of leukemia in the future.
Objective To systematically analyze the long-term trends in the disease burden and quality of care index (QCI) of pancreatitis in China from 1990 to 2023, and to evaluate the effectiveness of prevention and control measures as well as changes in care quality. MethodsData on the incidence, prevalence, mortality, and disability adjusted life years (DALYs) of pancreatitis were extracted from the Global Burden of Disease (GBD) 2023 study, and the QCI was constructed. Joinpoint regression, age-period-cohort modeling (Wald test), and autoregressive integrated moving average model were employed for analysis and forecasting. ResultsFrom 1990 to 2023, the age-standardized incidence rate of pancreatitis in China decreased by 32.9% (from 35.35 to 23.70 per 100 000 population), the age-standardized prevalence rate decreased by 31.3% (from 35.32 to 24.26 per 100 000 population), the age-standardized mortality rate decreased by 47.8% (from 0.81 to 0.42 per 100 000 population), the age-standardized DALYs rate decreased by 47.6% (from 25.00 to 13.10 per 100 000 population), the age-standardized years lived with disability rate decreased by 31.0% (from 2.72 to 1.87 per 100 000 population), and the age-standardized years of life lost rate decreased by 49.6% (from 22.28 to 11.23 per 100 000 population). However, the crude number of incident cases increased by 26.7% (from 363 200 to 460 400), the crude number of prevalent cases increased by 45.5% (from 353 800 to 514 800), the crude number of deaths increased by 36.2% (from 6 600 to 9 000), DALYs increased by 6.3% (from 247 000 to 262 500 person-years), years lived with disability increased by 39.5% (from 27 700 to 38 600 person-years), and years of life lost increased by 2.1% (from 219 300 to 223 900 person-years). The QCI increased from 89.58 to 93.29 [with an increase of 6.72 in females (from 87.96 to 94.68) and 1.60 in males (from 90.71 to 92.31)]. Age-period-cohort analysis showed that period effects were the primary driving factor, with significant effects on incidence (χ2=154.93, P<0.01) and prevalence (χ2=316.78, P<0.01), indicating that period effects were the main drivers of changes in disease burden. Autoregressive integrated moving average model projections indicated that by 2035, the crude prevalence rate will continue to rise to 37.06 per 100 000 population, the crude mortality rate will stabilize (approximately 0.70 per 100 000 population), the crude DALYs rate will decrease to 17.12 per 100 000 population, and the QCI will increase to 100. ConclusionsFrom 1990 to 2023, the age-standardized incidence rate, prevalence rate, mortality rate, DALYs rate, years lived with disability rate, and years of life lost rate of pancreatitis in China all decreased significantly, but the crude numbers of incident cases, prevalent cases, and deaths continued to increase. The QCI steadily improved, with greater improvement in females than in males. Significant age and gender disparities existed in disease burden, with period effects being the main driving factor. Projections indicate a future transition towards a chronic disease pattern. Enhanced interventions targeting high-risk populations and the development of a comprehensive chronic disease management system are warranted.